targeted antiviral therapies that could fill a critical gap in global public health preparedness. It also reinforces the joint commitment of CNCCS and IRBM to tackle rare and neglected diseases with innovative science. "Innovation in drug discovery...
and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization. CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of...
OCuSOFT® Retaine® Omega Forté™ Liquid Supplement is available through eyecare professionals and at www.ocusoft.com, and joins the company's existing lineup of trusted Retaine® brand products. About OCuSOFT Inc. OCuSOFT Inc. is a privately-held...
device, offering enhanced convenience and flexibility for healthcare providers. The 2-gram single-dose bottle joins the existing 1-gram version, giving clinicians more options for streamlined dosing and reconstitution in urgent bleeding scenarios....
approved therapies. OI is characterized by fragile bones and reduced bone mass resulting in bones that break easily, loose joints, and weakened teeth. In severe cases, those with OI may experience hundreds of fractures in a lifetime. In addition,...
play a central role in shaping the next stage of Orum’s technology innovation and pipeline growth. “The opportunity to join Orum at this stage of growth is incredibly compelling,” said Dr. May. “The Company’s Dual-Precision Targeted Protein...
Felstead, Chief Commercial Officer at Erbe Elektromedizin. Register for the free webinar "Advancing bariatric endoscopy" Join Prof. Ivo Boskoski, MD, Christopher McGowan, MD and Abdullah AlMousa, MD on 11 December for a live online session on the...
therapy. About the Collaboration between Eisai and Biogen for AD Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory...
of structural damage at 48 weeks. At Week 24, TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo with results consistent for patients with active PsA receiving TREMFYA® every four weeks...
scientifically rigorous, regulatory compliant, and strategically aligned with the company’s advancing portfolio. “Dennis joins Odyssey at a pivotal moment, as our lead programs advance toward later stages of development,” said Gary D. Glick, Ph.D.,...
have been published in the international journal Vaccine. BARYTHRAX is the world's first recombinant anthrax vaccine, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA). This randomized, double-blind,...
on transforming highly scalable core technologies into platforms and discovering diverse new drug candidates, including joint development with global pharmaceutical companies. About Samsung Bioepis Co., Ltd. Samsung Bioepis will continue to focus...
by partnering with one of the leading pillars of the Saudi Vision 2030 National Biotech Strategy. We were honored to be joined in the signing ceremony by our new partner, Prof. Mazen Hassanain, Managing Director and CEO of SVAX, and Hevolution...
In conjunction with the financing, both Ansuman Satpathy of Wing Venture Capital and Aiden Aceves of Insight Partners have joined Chemify’s Board of Directors. Founded in 2022 as a spin-out from the University of Glasgow, Chemify is reinventing...
Healthcare sector, driving a fivefold increase in net sales and a sevenfold rise in operating income since the company joined the Asahi Kasei Group in 2012. In its medium-term management plan, Asahi Kasei has indicated it will capitalize on this...
Dr. Tatsis has extensive senior-level leadership experience in global biopharmaceuticals companies. In 2017, Dr. Tatsis joined Vertex Pharmaceuticals and is responsible for managing all aspects of global regulatory affairs and quality assurance....
has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region. About lecanemab (Leqembi®: Lecanemab is the result of a strategic research alliance...
first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada. SCLC is aggressive...
mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation. IRRs can occur during or after the...
factor receptor 3 (EGFRxHER3) with a topoisomerase 1 inhibitor payload. Iza-bren is being developed by Biokin in China and jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories...
